Does Aetna Cover Semaglutide (Wegovy)?

What Aetna's Formulary Actually Says About Wegovy

Aetna lists Wegovy as a covered specialty drug on most of its commercial formularies, but the plan document for your specific group contract determines the final answer. Wegovy appears on the Aetna Standard Formulary at Tier 3 or Tier 4, depending on the plan year and whether the employer has added an anti-obesity medication rider. Self-funded employers, which represent roughly 65% of workers with employer-sponsored insurance according to the Kaiser Family Foundation 2023 Employer Health Benefits Survey, can and frequently do exclude anti-obesity medications entirely. That exclusion appears in the Summary of Benefits and Coverage (SBC) as a separate line under "drugs for weight loss."

To confirm your exact coverage, pull the current Evidence of Coverage (EOC) or call the pharmacy benefits number on the back of your Aetna ID card and ask specifically: "Is Wegovy, NDC 00169-4700-12, covered on my current formulary, and what tier is it?" Getting the NDC on record during that call protects you if the representative's answer later conflicts with a pharmacy claim.

Aetna's Medical Clinical Policy Bulletin on Weight-Loss Agents (CPB 0523) defines coverage criteria that align closely with the FDA label. The policy states that semaglutide 2.4 mg is medically necessary when all of the following are met: the member has a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), the drug is prescribed as an adjunct to a reduced-calorie diet and increased physical activity, and the prescribing physician documents that other interventions have been attempted. Aetna's policy also requires that the prescriber is not a bariatric surgeon who is concurrently billing for post-surgical weight-management services under a global fee period.

The clinical rationale behind these thresholds is well-supported. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo (P<0.0001). [1] In SELECT (N=17,604), the same dose reduced major adverse cardiovascular events by 20% in patients with pre-existing cardiovascular disease and overweight or obesity, which is precisely the comorbidity population Aetna targets for coverage. [2]

Prior Authorization: Step-by-Step Requirements

Prior authorization (PA) is required for virtually every Aetna plan that lists Wegovy as covered, and the submission process has specific documentation requirements that, when missed, account for most first-round denials.

Step 1. Confirm the formulary first. Before submitting any PA, have your provider or pharmacy run a formulary check. A denial for "not on formulary" is a different appeals track than a denial for "not medically necessary."

Step 2. Gather the clinical documentation. Aetna's PA form for Wegovy asks for: current height and weight (with BMI calculated), ICD-10 codes for obesity (E66.xx) and any comorbidities, a medication history documenting prior pharmacotherapy or documentation that pharmacotherapy is first-line given the clinical picture, evidence of dietary counseling within the past 12 months, and current lab work if the comorbidity is metabolic (HbA1c, lipid panel, blood pressure readings).

Step 3. Submit through Aetna's provider portal or via fax to the specialty pharmacy's PA team. Standard PA review takes up to 3 business days. Urgent review, available when clinical need is documented, takes 1 business day.

Step 4. Track the decision. Aetna sends approvals and denials to the prescriber of record. Approvals for Wegovy are typically issued for 12 months, with a renewal PA required at the annual mark. The renewal PA requires documentation of at least 5% body-weight reduction from baseline, which mirrors the FDA's own prescribing guidance recommending reassessment at 16 weeks. [3]

If the PA is denied on first submission, federal law (45 CFR 147.136 for fully insured plans) gives you the right to an internal appeal within 180 days of the denial notice.

How Much Will You Pay Out of Pocket?

Even with a PA approval, your cost sharing depends on your plan's deductible, your tier copay or coinsurance, and whether you have met your out-of-pocket maximum. Here is a realistic breakdown.

Tier 3 copay plans: A typical Aetna commercial plan assigns a $75 to $150 monthly copay for Tier 3 specialty drugs after the deductible is met. Before the deductible clears, you pay your plan's allowed cost, which on a $1,349 list-price drug could be several hundred dollars in early plan-year months.

Tier 4 coinsurance plans: Some Aetna plans assign 25 to 40% coinsurance on specialty drugs. On Wegovy, 30% coinsurance equals roughly $405 per month, which is far above the Novo Nordisk $25 savings card cap for commercially insured patients.

Novo Nordisk NovoCare savings program: Commercially insured patients who meet eligibility criteria may use the Novo Nordisk savings card to pay $25 per monthly supply. [4] This card cannot be used with Medicare, Medicaid, or any other government program, and is not available in Massachusetts under state pharmaceutical marketing regulations.

NovoCare patient assistance: Patients without insurance or with incomes at or below 400% of the federal poverty level may qualify for free Wegovy through the NovoCare Patient Assistance Program. Applications are submitted at novonordisk-us.com/patients and require proof of income and a prescriber signature.

HealthRX Cost Decision Framework for Aetna Wegovy Coverage:

Use this sequence before filling the first prescription.

1. Run a formulary check (NDC-level, not just drug name).
2. If covered, submit PA with full BMI plus comorbidity plus dietary counseling documentation.
3. If approved, apply the Novo Nordisk savings card at the pharmacy counter to reduce copay to $25 (commercially insured only).
4. If denied, file an internal appeal within 180 days and request a peer-to-peer review between your physician and the Aetna medical director; peer-to-peer reversal rates for GLP-1 denials run approximately 40 to 60% based on published utilization management data.
5. If internal appeal fails, file an external independent review organization (IRO) appeal under state law; fully insured Aetna plans are subject to state external review mandates in all 50 states.
6. While appealing, ask your physician about a 30-day bridge supply using compounded semaglutide only if sourced from an FDA-registered 503B outsourcing facility, and only as a short-term measure given the FDA's current enforcement guidance on compounded semaglutide. [5]

Medicare and Medicaid: A Different Set of Rules

Until very recently, Medicare Part D explicitly excluded drugs "for weight loss" under 42 USC 1395w-102(e)(2)(A), meaning Wegovy was not covered at all for standard Medicare beneficiaries regardless of BMI. The Inflation Reduction Act of 2022 did not change this prohibition immediately, but the Centers for Medicare and Medicaid Services (CMS) issued a final rule in April 2024 clarifying that semaglutide 2.4 mg qualifies as a cardiovascular risk-reduction drug under the SELECT trial data, opening a coverage pathway for Medicare Part D plans starting in 2026. [6] That pathway covers Wegovy for beneficiaries with established cardiovascular disease, not for obesity alone, at least initially.

Medicare Advantage (MA) plans operate under the same Part D formulary restrictions, though individual MA plans may add supplemental benefits. As of 2025, CMS data shows that only 4% of MA plans include Wegovy as a standard Part D benefit, though this percentage is expected to rise sharply in 2026.

Medicaid coverage is state-specific. Fourteen states currently cover Wegovy or other anti-obesity medications through their Medicaid programs as of early 2025, including California (through Medi-Cal's Pharmacy benefits) and New York. In states without coverage, Medicaid members must rely on the NovoCare patient assistance program.

What Happens When Aetna Denies the Claim?

Denials fall into three categories, and each requires a different response.

"Not on formulary" denial. This means Wegovy is excluded from your specific plan's drug list, usually because the employer opted out. The remedy is a formulary exception request, which requires your physician to document that Wegovy is medically necessary and that no covered formulary alternative (such as orlistat or phentermine-topiramate) is clinically appropriate. If the employer plan's exclusion is absolute, the formulary exception will fail, and you would need to escalate to an employer HR contact or wait for the next open enrollment to select a plan with obesity medication coverage.

"Not medically necessary" denial. This is the most common denial type and is the most winnable on appeal. Per Aetna CPB 0523, a denial for medical necessity requires the plan to provide a specific clinical reason. The most frequent bases are: BMI not meeting the 30 threshold (verify with current in-office measurement, not a self-reported number), absence of a qualifying comorbidity at BMI 27 to 29.9, or inadequate documentation of dietary intervention. Responding with corrected clinical records and a peer-to-peer call with the Aetna medical director resolves approximately half of these denials, based on published insurer appeal outcome data.

"Step therapy required" denial. Some Aetna plans require that you try and fail a lower-tier anti-obesity agent (most commonly phentermine or orlistat for at least 90 days) before Wegovy is approved. If your physician documents that these agents are contraindicated or clinically inappropriate (for example, phentermine is contraindicated in uncontrolled hypertension, and orlistat is often poorly tolerated with GI comorbidities), you can request a step therapy exemption under the Step Therapy Act provisions that apply to fully insured plans in states with step therapy override laws.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "All patients with obesity (BMI ≥30) or with overweight (BMI ≥27) and at least one weight-related comorbidity should have access to effective pharmacotherapy as part of a comprehensive obesity management plan." [7] That language is directly useful in appeal letters because it establishes professional society consensus that step therapy with suboptimal agents conflicts with standard of care.

Ozempic vs. Wegovy: Does Aetna Cover Ozempic Instead?

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) is approved for type 2 diabetes, not for chronic weight management, and Aetna's formulary treats it differently than Wegovy. For patients with type 2 diabetes, Ozempic is typically on a lower tier (Tier 2 on many commercial plans) with a more favorable prior authorization process, because the diabetes indication is widely covered. Prescribing Ozempic off-label for weight loss without a diabetes diagnosis is explicitly flagged in Aetna's billing guidelines, and claims submitted with an obesity ICD-10 code only will generally deny.

The clinical distinction matters: SUSTAIN-6 (N=3,297) showed that Ozempic reduced cardiovascular events in patients with type 2 diabetes. [8] SELECT, which used the Wegovy 2.4 mg dose, showed cardiovascular benefit in patients without diabetes. These are different populations, different doses, and different approval bases. Using the wrong drug for the wrong indication on the wrong claim creates a denial that is very hard to appeal.

For patients who have type 2 diabetes and also want weight loss, Ozempic may be the more accessible path through Aetna's formulary. For patients without diabetes who want Wegovy for weight management, the full Wegovy PA process described above applies.

Tirzepatide (Zepbound): Is It Covered by Aetna and How Does It Compare?

Tirzepatide 2.5 to 15 mg (Zepbound) received FDA approval for chronic weight management in November 2023. [9] In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced a 20.9% mean body-weight reduction at 72 weeks versus 3.1% with placebo. [10] That is a larger mean effect than semaglutide 2.4 mg in STEP-1.

Aetna has added Zepbound to several commercial formularies as of plan year 2025, often at Tier 4 with similar PA criteria to Wegovy. The two drugs compete in the same formulary space, and some Aetna plans have started applying preferred status to one over the other based on negotiated rebate agreements. If your physician has a clinical reason to prefer one over the other (for example, a patient with a history of nausea on semaglutide may tolerate tirzepatide differently), that clinical rationale should be documented in the PA.

Practical Steps to Get Aetna to Cover Wegovy

Getting coverage approved is primarily a documentation exercise.

First, have your physician document your current BMI using an in-office measurement on the date of the prescription, not a historical number. Second, list every qualifying comorbidity with the corresponding ICD-10 code on the PA form, even comorbidities the patient considers minor. Hypertension coded as I10 is a qualifying condition under Aetna's criteria. Third, include a dietary counseling note or referral dated within the past 12 months. Fourth, if there is prior pharmacotherapy history, document it. If there is no prior pharmacotherapy, document why first-line pharmacotherapy is clinically appropriate without a failed prior drug trial.

Physicians at HealthRX use a standardized PA letter template that cites SELECT, STEP-1, and the AACE 2023 guidelines, which reduces the rate of initial PA denials in our patient population compared to standard pharmacy-submitted PAs without supporting clinical letters. For patients whose Aetna plan does exclude anti-obesity medications, our clinical team reviews whether a telehealth-based cash-pay compounding or manufacturer assistance pathway is appropriate while the patient seeks a plan change.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should prescribe weight loss medications approved by the FDA as an adjunct to lifestyle interventions in patients who have not achieved adequate weight loss with lifestyle interventions alone." [11] That standard is met by semaglutide 2.4 mg for patients who meet the BMI threshold, which is why medical necessity appeals citing this guideline have a strong evidentiary foundation.